These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 32832675)
1. Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations. Mandal A; Kumbhojkar N; Reilly C; Dharamdasani V; Ukidve A; Ingber DE; Mitragotri S Sci Adv; 2020 Jul; 6(30):eabb6049. PubMed ID: 32832675 [TBL] [Abstract][Full Text] [Related]
2. IkBζ is a Key Regulator of Tumour Necrosis Factor-a and Interleukin-17A-mediated Induction of Interleukin-36g in Human Keratinocytes. Ovesen SK; Schulze-Osthoff K; Iversen L; Johansen C Acta Derm Venereol; 2021 Feb; 101(2):adv00386. PubMed ID: 33491092 [TBL] [Abstract][Full Text] [Related]
3. The human IL-17A/F heterodimer regulates psoriasis-associated genes through IκBζ. Bertelsen T; Iversen L; Johansen C Exp Dermatol; 2018 Sep; 27(9):1048-1052. PubMed ID: 29938836 [TBL] [Abstract][Full Text] [Related]
4. IκBζ is a key player in the antipsoriatic effects of secukinumab. Bertelsen T; Ljungberg C; Litman T; Huppertz C; Hennze R; Rønholt K; Iversen L; Johansen C J Allergy Clin Immunol; 2020 Jan; 145(1):379-390. PubMed ID: 31622687 [TBL] [Abstract][Full Text] [Related]
5. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis. Yadav K; Singh D; Singh MR; Pradhan M Med Hypotheses; 2020 Dec; 145():110322. PubMed ID: 33086162 [TBL] [Abstract][Full Text] [Related]
6. Topical delivery of siRNA into skin using ionic liquids. Dharamdasani V; Mandal A; Qi QM; Suzuki I; Bentley MVLB; Mitragotri S J Control Release; 2020 Jul; 323():475-482. PubMed ID: 32339547 [TBL] [Abstract][Full Text] [Related]
7. SERPINB2 and miR-146a/b are coordinately regulated and act in the suppression of psoriasis-associated inflammatory responses in keratinocytes. Vaher H; Kivihall A; Runnel T; Raam L; Prans E; Maslovskaja J; Abram K; Kaldvee B; Mrowietz U; Weidinger S; Kingo K; Rebane A Exp Dermatol; 2020 Jan; 29(1):51-60. PubMed ID: 31630447 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus Inhibits TNF-α/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IκBζ. Hu Y; Guo J; Yin L; Tu J; Yin Z Inflammation; 2020 Apr; 43(2):692-700. PubMed ID: 31838663 [TBL] [Abstract][Full Text] [Related]
9. TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression. Urbano PCM; Aguirre-Gamboa R; Ashikov A; van Heeswijk B; Krippner-Heidenreich A; Tijssen H; Li Y; Azevedo VF; Smits LJT; Hoentjen F; Joosten I; Koenen HJPM J Allergy Clin Immunol; 2018 Aug; 142(2):517-529. PubMed ID: 29248493 [TBL] [Abstract][Full Text] [Related]
10. Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis. Qiong H; Han L; Zhang N; Chen H; Yan K; Zhang Z; Ma Y; Xu J BMC Immunol; 2021 May; 22(1):34. PubMed ID: 34044769 [TBL] [Abstract][Full Text] [Related]
11. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase. Depieri LV; Borgheti-Cardoso LN; Campos PM; Otaguiri KK; Vicentini FT; Lopes LB; Fonseca MJ; Bentley MV Eur J Pharm Biopharm; 2016 Aug; 105():50-8. PubMed ID: 27224855 [TBL] [Abstract][Full Text] [Related]
13. NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis. Coto-Segura P; González-Lara L; Batalla A; Eiris N; Queiro R; Coto E Mol Diagn Ther; 2019 Oct; 23(5):627-633. PubMed ID: 31267486 [TBL] [Abstract][Full Text] [Related]
14. Transdermal delivery of Fn14 siRNA using a novel composite ionic liquid for treatment of psoriasis-like skin lesions. Li L; Wu X; Wu J; Zhang X; Miao F; Wang J; Lu J; Liu J; Chen Z; Tai Z; Zhu Q J Control Release; 2024 Jan; 365():818-832. PubMed ID: 38070601 [TBL] [Abstract][Full Text] [Related]
15. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Furue K; Ito T; Furue M Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115 [TBL] [Abstract][Full Text] [Related]
16. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906 [TBL] [Abstract][Full Text] [Related]
17. Biologics in pediatric psoriasis. Wang WM; Jin HZ J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087 [TBL] [Abstract][Full Text] [Related]
18. IL-17A synergistically enhances TLR3-mediated IL-36γ production by keratinocytes: A potential role in injury-amplified psoriatic inflammation. Liu S; Wu F; Wu Z; Li Y; Zhang S; Yu N Exp Dermatol; 2019 Mar; 28(3):233-239. PubMed ID: 30614571 [TBL] [Abstract][Full Text] [Related]
19. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice. Liu Z; Liu H; Xu P; Yin Q; Wang Y; Opoku YK; Yang J; Song L; Sun X; Zhang T; Yu D; Wang X; Ren G; Li D Biomed Pharmacother; 2018 Dec; 108():1425-1434. PubMed ID: 30372845 [TBL] [Abstract][Full Text] [Related]
20. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Johnston A; Guzman AM; Swindell WR; Wang F; Kang S; Gudjonsson JE Br J Dermatol; 2014 Jul; 171(1):97-107. PubMed ID: 24601997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]